Overview

Pilot Study of Lubiprostone as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Persons With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy

Status:
Unknown status

Trial end date:
2015-06-01

Target enrollment:

Participant gender:

Summary

The use of lubiprostone will decrease the levels of immune activation in HIV-infected subjects with incomplete CD4+ T-cell recovery with antiretroviral therapy (ART). - Lubiprostone will decrease levels of translocated gut microbial products in HIV-infected subjects with incomplete CD4+ T-cell recovery with ART. - The decrease in levels of translocated gut microbial products will be associated with a decline in the levels of immune activation in HIV-infected subjects with incomplete CD4+ T-cell recovery with ART.

Phase:

Phase 2

Details

Lead Sponsor:

Ruth M. Rothstein CORE Center

Treatments:

Lubiprostone